预约演示
更新于：2026-02-02
Sodium Picosulfate Hydrate
匹可硫酸钠
更新于：2026-02-02
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1979-08-27), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H17NNa2O9S2 |
InChIKeyPUKNPYFKPBSERR-UHFFFAOYSA-N |
CAS号1307301-38-7 |
关联
46
项与 匹可硫酸钠 相关的临床试验CTRI/2025/03/083129
A Pilot study to Evaluate the Effectiveness and Safety of Combination of Milk of Magnesia, Liquid Paraffin, and Sodium Picosulfate Oral Emulsion for Treatment of Chronic Constipation in Patients with Comorbidities
IRCT20250526065902N1
Comparing the efficacy of split-dose sodium picosulfate/ mangnesium citrate (SPMC) regimen versus polyethylene glycol (PEG) for colonoscopy preparation in outpatients: A Randomized Clinical Traial
CTRI/2024/07/070750
A Prospective, Multicentric Study, To Evaluate The Effectiveness And Safety Of Milk Of Magnesia+Liquid Paraffin+Sodium Picosulfate In The Treatment Of Constipation Symptoms In Post Ano-Rectal Surgical Patients - NA
100 项与 匹可硫酸钠 相关的临床结果
登录后查看更多信息
100 项与 匹可硫酸钠 相关的转化医学
登录后查看更多信息
100 项与 匹可硫酸钠 相关的专利（医药）
登录后查看更多信息
210
项与 匹可硫酸钠 相关的文献（医药）2025-12-01Lancet Child & Adolescent Health
Efficacy and safety of pharmacological therapies for functional constipation in children: a systematic review and meta-analysis
Review
作者: Sinopoulou, Vassiliki ; de Geus, Anna ; Gordon, Morris ; Benninga, Marc A ; Liu, Shiyao ; Tabbers, Merit M ; Thornton, Alexander J ; Arruda Navarro Albuquerque, Daniel ; Ajiboye, Aderonke
BACKGROUND:
There has been a substantial increase in studies on functional constipation in children as new therapies are deployed. We aimed to provide an up-to-date, methodologically robust systematic review and meta-analysis on the efficacy and safety of pharmacological therapies for functional constipation in children.
METHODS:
In this systematic review and meta-analysis, we searched PubMed, Medline, Embase, and the Cochrane library from inception to Feb 5, 2025. We included randomised controlled trials that involved children aged 0 years to younger than 18 years with functional constipation treated with pharmacological interventions compared with placebo, no treatment, or other interventions and with at least a 2-week follow-up period. Studies were excluded if there was no definition of functional constipation, children with organic causes for constipation or previous bowel surgery were included, children with faecal incontinence without the presence of constipation were included, or the aim of treatment was faecal disimpaction rather than maintenance therapy. Pairs of authors independently extracted summary data from published reports and critiqued studies. We assessed risk of bias with the Cochrane tool. Meta-analyses estimated risk ratios (RRs) or mean differences, and 95% CIs. Certainty of evidence was established with GRADE. Our main outcomes were treatment success (as defined by study authors), defecation frequency, and withdrawals due to adverse events. This study was registered on PROSPERO (CRD42022368719).
FINDINGS:
Our search identified 4595 articles, of which 59 randomised controlled trials were included, representing 7045 participants with functional constipation. Interventions included polyethylene glycol (n=36 studies), lactulose (n=18), magnesium oxide or magnesium hydroxide (n=7), picosulfate (n=1), liquid paraffin (n=4), prucalopride (n=1), lubiprostone (n=2), linaclotide (n=3), plecanatide (n=1), enemas (n=2), and domperidone (n=1). Meta-analyses for treatment success showed that polyethylene glycol was probably more effective than placebo (RR 1·74 [95% CI 1·25-2·41], moderate certainty of evidence) and may be more effective than lactulose (1·35 [1·11-1·64], low certainty of evidence). There might be no difference in treatment success for linaclotide compared with placebo (1·21 [0·69-2·13], low certainty of evidence), but linaclotide probably leads to higher defecation frequency per week (mean difference 1·10 [95% CI 0·40-1·80], moderate certainty of evidence). There is low to moderate certainty evidence that prucalopride is not more effective than placebo (RR 1·68 [95% CI 0·77 to 3·68]).
INTERPRETATION:
Polyethylene glycol is probably more effective than placebo and key comparator therapies and should be considered the standard of first-line care. Future studies should consider polyethylene glycol as an index therapy, and clearly describe methods, patient characteristics, and previous therapeutics.
FUNDING:
None.
2025-08-01BRAIN & DEVELOPMENT
Prevalence and management of gastrointestinal complications in Duchenne muscular dystrophy: A retrospective cohort study
Article
作者: Oba, Mari ; Takeshita, Eri ; Saito, Takashi ; Ito, Yusuke ; Sumitomo, Noriko ; Aihara, Yu ; Yamamoto, Kaoru ; Baba, Shimpei ; Komaki, Hirofumi ; Shimizu-Motohashi, Yuko ; Yamamoto, Hisako
BACKGROUND:
Gastrointestinal complications in Duchenne muscular dystrophy (DMD) have been understudied, particularly in Asian populations. This study aimed to determine the frequency and clinical characteristics of gastrointestinal complications.
METHODS:
This single-center, retrospective study reviewed medical records of 459 Asian patients with genetically or biopsy-confirmed DMD, aged 1-48 years, from September 1, 2010, to January 1, 2023.
RESULTS:
Constipation was the most common complication, affecting 149 patients (32.5 %), followed by dysphagia in 43 patients (9.4 %). Other conditions included irritable bowel syndrome in 8, gastroesophageal reflux disease in 7, hemorrhoids in 6, acute dilatation of stomach in 4, sigmoid colon volvulus in 2, and pneumatosis cystoides intestinalis in 2. Additionally, 1 case each of appendicitis, esophageal diverticulum, paralytic ileus, aerophagia, anal atresia, malabsorption syndrome, fecal incontinence, inflammatory bowel disease, gastrointestinal bleeding, and rectal prolapse was observed. Treatments for constipation included no intervention in 20 patients (13.4 %), sodium picosulfate hydrate in 62 (41.6 %), magnesium oxide in 59 (39.6 %), and polyethylene glycol 4000 in 20 (13.4 %). Logistic regression analysis showed that body mass index (BMI), age and angiotensin converting enzyme inhibitor use was significantly associated with constipation.
CONCLUSIONS:
This study highlighted constipation as the most frequent gastrointestinal complication in DMD and identified several rare but serious complications, offering key insights into real-world clinical practice.
2025-04-01TALANTA
A smartphone-based dual-modal lateral flow immunochromatographic assay for multiplex detection of illegal stimulant laxatives in slimming foods
Article
作者: Chen, Sha ; Lei, Hongtao ; Chen, Jiahong ; Xu, Zhenlin ; Liang, Shuiyuan ; Guan, Tian
Stimulant laxatives (especially bisacodyl and sodium picosulfate) are frequently found to be adulterated into slimming foods, causing health-threatening effects to consumers. Sensitive, accurate, easy-to-operate and portable multiplex analytical techniques are still desired for the rapid screening of stimulant laxatives in slimming foods. In this work, a highly sensitive dual-modal colorimetric/photothermal lateral flow immunochromatographic assay (LFIA) was established based on facilely prepared concentrated gold nanoparticles (cAuNPs). Due to the enhanced local surface plasmon resonance and absorption intensity of our unique cAuNPs, this LFIA can simultaneously detect bisacodyl, bis-(p-hydroxyphenyl)-pyridyl-2-methane and sodium picosulfate in slimming food as low as 0.014-0.308 ng/mL by a smartphone-based photothermal device or 1.4-10 ng/mL by naked eyes. Compared with traditional AuNPs-LFIA, it demonstrated 8.48-10.27 times higher sensitivity in photothermal mode. Moreover, in the recovery test and blind sample analysis, this dual-modal LFIA exhibited reasonable recoveries (85.04 %-119.18 %) and high correlation with authorized LC-MS/MS method, suggesting high accuracy and applicability. This work offers a highly sensitive, accurate and convenient way for the on-site determination of stimulant laxatives, which can also be employed to detect other food hazards, environmental pollutants, or clinical analytes within a few minutes.
100 项与 匹可硫酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 造影剂 | 日本 | 1992-07-01 | |
| 肠道准备 | 日本 | 1992-03-27 | |
| 便秘 | 日本 | 1979-08-27 | |
| 便秘 | 日本 | 1979-08-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胃肠道疾病 | 临床3期 | 法国 | 2014-11-01 | |
| 胃肠道疾病 | 临床3期 | 德国 | 2014-11-01 | |
| 胃肠道疾病 | 临床3期 | 荷兰 | 2014-11-01 | |
| 弥漫性大B细胞淋巴瘤 | 临床3期 | 日本 | 2014-09-01 | |
| 功能性便秘 | 临床3期 | 中国 | 2011-09-16 | |
| 药用辅料 | 临床3期 | 美国 | 2010-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 862 | Standard dosing | 淵壓鹹繭窪網鹽醖繭膚(餘糧遞選簾廠選壓鑰夢) = 艱鑰鹹鏇鑰觸顧範醖獵 遞願獵齋選艱夢顧範鬱 (窪鹽築鏇築鬱醖襯醖觸 ) | - | 2014-08-01 | |
Split dosing | 淵壓鹹繭窪網鹽醖繭膚(餘糧遞選簾廠選壓鑰夢) = 齋願餘壓膚鬱觸鹹廠淵 遞願獵齋選艱夢顧範鬱 (窪鹽築鏇築鬱醖襯醖觸 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用